Community [geoa]
long-term care [hlca]
Management [ocac]
Parkinson Disease [dsyn]
Elderly [popg]
Focus [spco]
Monoamine Oxidase Type B Inhibitor [phsu]
Parkinson Disease [dsyn]
Affect [menp]
Million [qnco]
People [popg]
Elderly [popg]
Motor [ftcn]
Motor symptoms [sosy]
Point [qnco]
Institutionalization [hlca]
Age [orga]
drug absorption [phsf]
distribution [idcn]
Metabolism [orgf]
Excretion [phsf]
complicate [ftcn]
treatment [ftcn]
Elderly [popg]
Patients [podg]
Parkinson Disease [dsyn]
General [spco]
Management [ocac]
Initiation [menp]
Medication [phsu]
Low dose [qnco]
Gradual [qlco]
Titration [lbpr]
Based [ftcn]
effects [qlco]
Avoidance [menp]
Certain [qlco]
Class [inpr]
Drugs [phsu]
Anticholinergics [phsu]
Attention [menp]
Polypharmacy [fndg]
toxic [inpo]
Drug Interactions [moft]
Levodopa [aapp, nsba, phsu]
Efficacy [qlco]
Parkinson Disease [dsyn]
Medication [phsu]
therapy [ftcn]
Elderly [popg]
Parkinson Disease [dsyn]
Dopamine Receptor Agonists [phsu]
Amantadine [orch, phsu]
anticholinergic drugs [phsu]
Elderly [popg]
Limited [ftcn]
High Risk [qlco]
Catechol O-Methyltransferase Inhibitors [moft]
augment [qnco]
Levodopa [aapp, nsba, phsu]
setting [ftcn]
i e [diap, inpr]
Motor fluctuation [ftcn]
Monoamine Oxidase Type B Inhibitor [phsu]
Spectrum [qnco]
disease severity [qlco]
Selegiline [orch, phsu]
Deprenyl [orch, phsu]
Class [inpr]
Bioavailability [qnco]
parent [famg]
Drug [phsu]
Conversion [ftcn]
Amfetamine [nsba, orch, phsu]
Metabolites [bacs]
adverse events [fndg]
Orally [spco]
DISINTEGRATE [phpr]
Tablet [bodm]
Formulation [resa]
Overcome [acty]
limitations [ftcn]
rasagiline [orch, phsu]
Second [qnco]
Generation [tmco]
Monoamine Oxidase Type B Inhibitor [phsu]
Chemically [chem]
Selegiline [orch, phsu]
Favorable [qlco]
Safety [hcpp]
Profile [lbpr]
rasagiline [orch, phsu]
Elderly [popg]
Daily [tmco]
Formulation [resa]
Drug [phsu]
Adherence [ftcn]
